1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global HIV Vaccine Market Future Outlook

Global HIV Vaccine Market Future Outlook

  • May 2015
  • 275 pages
  • ID: 4397221
  • Format: PDF
  • Kuick Research


Table of Contents

Vaccine discovery, designing, research and development science is backed by several decades of knowledge. Every year, new vaccine for treating infectious diseases is entering in the market and their quality along with pharmacological efficacy is increasing. Innovative modalities have been found and market is overcrowded with the number of vaccines for different infectious diseases. In this scenario, absence of HIV vaccines becomes a pertinent question in front of investigators funded by both pharmaceutical companies and medical regulatory authorities. Gravity of the situation could also be understood by the fact that HIV clinical trials have failed to produce pharmacological benefits despite availability of suitable infrastructure. Simultaneously, HIV incidences are escalating tremendously across the globe due to which necessity for this vaccine is becoming more essential. All these facts support the imminent market introduction of HIV vaccines in global market to prevent progression and proliferation of AIDS epidemic.

Clinical trials are being done for across the globe for development of HIV vaccines and these efforts have yielded significant results. Investigators have identified artificial molecules that could mimic the HIV infection as result of which immune system would be activated. Their efficacy has been proved and clinical trials using them have yet to instigate. Several different modalities are also under investigation which may lead to development of relatively high cure rates. Certain receptors are also under investigation which has been found to be involved during initial phase of HIV infection. Immunoglobins may also serve as an ideal candidate due to their involvement in immune system activation. Beside this, several innovative modalities has been proposed for the treatment of HIV and emphasis is being given on the development of prophylactic vaccines. Several lead molecules have been discovered and their pharmacological efficacy is under investigation. In this way, investigators are expected to find some worthy candidate to the development of HIV vaccine.

Recombinant DNA technologies and genetic engineering has been widely used for the development of vaccines for several infectious diseases. These technologies are also being used for the development of HIV vaccines that would be commercialized in global market in coming years. Genetic manipulation of HIV is under consideration to develop a strain which have all molecular signatures but no pathogenicity. This decoy strain will activate the immune system to develop active immunity. Novel modalities include, use of recombinant molecules having higher immune eliciting capabilities. Computerized simulations are also being used for analysis of obscure vaccine candidates having pharmaceutical potential. This technology is expected to decrease the valuable time and precious resources utilized in the screening of proposed candidate. Furthermore, investigators are developing methodologies to find the effect of HIV gene expression on nonpathogenic bacterial/viral vectors.

Pharmaceutical companies have recognized the dearth of effective HIV medications due to which they are investing significant amount on research and development of HIV vaccines. Various candidates are at different stages of clinical trials and they would be introduced in market in coming years. Technology is developing at rapid rates due to which screening of selected candidate is expected to take place at lesser time. In this way, market winding times are expected to decrease due to lesser time in developmental phases. Manufacturing capabilities are highly developed but some tweaking has to be done according to HIV pathogen. Significant development in recombinant DNA technology and genetic engineering is also expected to accelerate the rate of HIV vaccine development. Investigators are also expected to find new modalities that will help in checking the AIDS. In this way, future of HIV vaccines market looks optimistic and it may be commercialized in next 5-10 years.

"Global HIV Vaccine Market Future Outlook" Report Highlights:

Introduction to HIV Vaccines
Issues Related to the Development of HIV Vaccines
Parameters for Successful Commercialization of HIV Vaccines
Global HIV Vaccines Market Opportunity Analysis
Global HIV Vaccine Clinical Pipeline by Company & Phase
Global HIV Vaccine Clinical Pipeline: 100 Vaccines
Majority Vaccine in Preclinical Phase: 42 Vaccines

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on